A report from a UK clinical consensus on PSA blood testing
Our limited-time only webinar that was recorded at the Guidelines conference in November 2024, about optimising the use of the PSA blood test in asymptomatic men for early prostate cancer detection in primary care. *This recording will expire in November 2025*
PSA diagnostic case studies
Dr Sam Merriel and Dr Olly Hulson cover some case studies common to Primary Care, to explore early diagnosis and diagnostic pathways through real-world scenarios.
Using real world data to bridge the evidence gap left by prostate cancer screening trials
How Real-World Data can demonstrate reduction in harms of prostate cancer screening and inform the future of diagnostics to improve early diagnosis.
The modern prostate cancer diagnostic pathway
Dr. Olly Hulson provides an overview of the modern prostate cancer diagnostic pathway.
PSA consensus recommendations and implications for practice
Dr. Sam Merriel presents PSA consensus recommendations and implications for practice.
Lived experience conversation
Meg Burgess, Specialist Nurse at Prostate Cancer UK, leads a lived experience conversation with Tony, Junior, and Patrick.
Prostate mpMRI in the UK: the state of the nation
The article discusses how advancements in multiparametric MRI (mpMRI) are enhancing prostate cancer diagnosis by reducing unnecessary biopsies and targeting significant cancers, despite ongoing challenges like geographical variation and limited resources.
Optimising the use of the prostate- specific antigen blood test in asymptomatic men for early prostate cancer detection in primary care: report from a UK clinical consensus
The report examines the optimal use of the PSA test for detecting prostate cancer in asymptomatic UK men, recommends proactive testing for those at higher risk, and suggests reviewing existing guidelines to improve screening practices.
The impact of pre-biopsy MRI and additional testing on prostate cancer screening outcomes: A rapid review
The article finds that adding pre-biopsy MRI to standard PSA testing improves the detection of significant prostate cancers, reduces diagnoses of less severe cases, and helps many men avoid unnecessary biopsies, though its long-term impact on prostate cancer-specific mortality remains uncertain.
How to improve the quality of your MRI
Prostate Cancer UK is analyzing the PRIME trial and GLIMPSE study’s groundbreaking MRI results to assess their potential impact on men with prostate cancer.
